2017
Design and implementation of a factorial randomized controlled trial of methadone maintenance therapy and an evidence-based behavioral intervention for incarcerated people living with HIV and opioid dependence in Malaysia
Bazazi AR, Wickersham JA, Wegman MP, Culbert GJ, Pillai V, Shrestha R, Al-Darraji H, Copenhaver MM, Kamarulzaman A, Altice FL. Design and implementation of a factorial randomized controlled trial of methadone maintenance therapy and an evidence-based behavioral intervention for incarcerated people living with HIV and opioid dependence in Malaysia. Contemporary Clinical Trials 2017, 59: 1-12. PMID: 28479216, PMCID: PMC5557499, DOI: 10.1016/j.cct.2017.05.006.Peer-Reviewed Original ResearchConceptsMethadone maintenance therapyHIV transmission risk behaviorsMaintenance therapyTransmission risk behaviorsEvidence-based behavioral interventionsOpioid dependencePoor HIV treatment outcomesRisk behaviorsBehavioral interventionsHIV treatment outcomesProspective clinical trialsEvidence-based treatmentsHealth-related outcomesOpioid useTreatment receiptClinical trialsTreatment outcomesIncarcerated peopleTherapyStudy participantsFactorial trialHIVTrialsInterventionOutcomesAn explanatory factor analysis of a brief self-report scale to detect neurocognitive impairment among HIV-positive men who have sex with men and transgender women in Peru
Weikum D, Shrestha R, Ferro EG, Vagenas P, Copenhaver M, Spudich S, Alpert MD, Cabello R, Lama JR, Sanchez J, Altice FL. An explanatory factor analysis of a brief self-report scale to detect neurocognitive impairment among HIV-positive men who have sex with men and transgender women in Peru. AIDS Care 2017, 29: 1297-1301. PMID: 28449599, PMCID: PMC6337065, DOI: 10.1080/09540121.2017.1322681.Peer-Reviewed Original ResearchConceptsHIV-positive menNeuropsychological Impairment ScaleNeurocognitive impairmentTransgender womenAntiretroviral therapyHIV-positive MSMPoor clinical outcomeHIV risk behaviorsClinical care settingsHealth-related outcomesExploratory factor analysisART adherenceClinical outcomesPatient populationCare settingsImpairment ScaleRisk behaviorsImpairmentMenPrincipal axis factoringSelf-report scalesOrthogonal varimax rotationWomenBrief self-report scaleOutcomes
2010
Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs
Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. The Lancet 2010, 376: 367-387. PMID: 20650518, PMCID: PMC4855280, DOI: 10.1016/s0140-6736(10)60829-x.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related Opportunistic InfectionsAnti-HIV AgentsAntipsychotic AgentsAntitubercular AgentsAntiviral AgentsBacterial InfectionsComorbidityCriminal LawDrug InteractionsDrug Resistance, BacterialEvidence-Based MedicineHepatitis, Viral, HumanHIV InfectionsHumansMedication AdherenceMental DisordersNarcoticsPrisonersSubstance-Related DisordersTuberculosisConceptsSubstance use disordersDrug usersAntiretroviral therapyViral hepatitisHIV treatmentHealth of HIVPharmacokinetic drug interactionsSubstance use comorbiditiesMedication-assisted therapyEvidence-based treatmentsDrug-resistant strainsHealth-related outcomesHealth service deliveryInfectious complicationsMultiple comorbiditiesHIV infectionPsychiatric comorbidityPoor adherenceClinical managementCardiovascular diseaseInadequate prescriptionCongregate settingsDrug interactionsComorbiditiesHIV